Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414791 | 0.77 | NAMPT (0.46) | ACACBNAMPT | |
| SCHEMBL28317573 | 0.75 | ALDH1A1 (0.44) | ACACBNAMPTHRH2HRH1 | |
| SCHEMBL2928096 | 0.74 | — | — | |
| SCHEMBL8916525 | 0.72 | — | — | |
| SCHEMBL3146758 | 0.71 | KMT2A (0.49) | — | |
| SCHEMBL23042189 | 0.70 | CHRNA4 (0.36) | ACACBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3139874 | 0.68 | ALDH1A1 (0.35) | ACACBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL249355 | 0.68 | — | — | |
| SCHEMBL888662 | 0.67 | CHRNA4 (0.39) | ACACBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27892844 | 0.67 | CHRNA4 (0.44) | ACACBCHRNA4CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197879-B1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-01-22 | — | — | EP | claimed |
| EP-2197879-A1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-06-23 | — | — | EP | claimed |
| US-7687496-B2 | C7-substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | claimed |
| WO-2009051580-A1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20090099224-A1 | C7- substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099224-A1 | C7- substituted camptothecin analogs | ABCB1, ABCC1, ABCG2 | ACACB 3272/4885CHRNA4 4637/4885CHRNB2 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.